Zhejiang Haiding Pharmaceutical Co., Ltd. announced that it will receive CNY 50 million in an equity round of funding on February 18, 2016. The transaction will include participation from a new investor, Guizhou Xinbang Pharmaceutical Co., Ltd. (SZSE:002390). As part of the transaction, the investor will acquire 83.33% stake in the company.

Upon closing, the registered capital will increase from CNY 10 million to CNY 60 million. The stake of Chinese Peptide Company Ltd. will dilute from 100% to 16.67%. The transaction was approved in the 10th session of its 6th directorate of the investor.